NCT07204249

Glutide for Ending Methamphetamine

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 162 (estimated)
• Sponsor: San Francisco Department of Public Health · Other Government
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

GEM is a two-phase study to evaluate the use of semaglutide (Wegovy) for the treatment of methamphetamine use disorder (MeUD). The first phase is a pilot study, which will be an open-label, single-arm pilot study of 25 participants. Participants will receive Wegovy over a 12-week treatment period, with a subsequent follow-up visit at week 20. This phase will evaluate the feasibility, acceptability, and preliminary efficacy of Wegovy for MeUD. The second phase will be a phase IIb randomized-controlled trial to determine the efficacy of Wegovy in treating MeUD. This trial will be similar to the pilot with randomization to Wegovy or placebo and blinding of group assignment. The trial will enroll 162 participants across two sites.

Conditions

• Methamphetamine-dependence

Interventions

Type	Name	Description
DRUG	Semaglutide	Semaglutide
DRUG	Placebo	Placebo

Timeline

• Start date: 2026-01-15
• Primary completion: 2030-02-15
• Completion: 2030-02-15
• First posted: 2025-10-02
• Last updated: 2025-10-21

Regulatory

• FDA-regulated drug study